Mafei Kang
Guilin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: March 27, 2025
Efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin or nedaplatin plus tegafur/gimeracil/oteracil as induction chemotherapy regimen for hypopharyngeal cancer.
Journal: Frontiers in oncology
Published: October 01, 2024
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: September 29, 2024
Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review.
Journal: Oncology letters
Published: April 29, 2024
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 04, 2024
Deletion of IL-27p28 induces CD8 T cell immunity against colorectal tumorigenesis.
Journal: International immunopharmacology
Published: September 26, 2023
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 26, 2023
Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study.
Journal: Radiology and oncology
Published: February 16, 2023
Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region-anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib.
Journal: Frontiers in oncology
Published: August 17, 2022
Integrative analyses of RNA-seq and ChIP-seq Reveal MITF as a Target Gene of TFPI-2 in MDA231 Cells.
Integrative analyses of RNA-seq and ChIP-seq Reveal MITF as a Target Gene of TFPI-2 in MDA231 Cells.
Journal: Biochemical genetics
Published: April 27, 2022
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.
Journal: Therapeutic advances in medical oncology
Published: December 21, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Journal: Cancer communications (London, England)
Published: January 16, 2021
Last Updated: 09/26/2026